- Home
- DHF vs GNFT Comparison
DHF vs GNFT Comparison
Compare DHF & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- GNFT
- Stock Information
- Founded
- DHF 1998
- GNFT 1999
- Country
- DHF United States
- GNFT France
- Employees
- DHF N/A
- GNFT N/A
- Industry
- DHF Finance Companies
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHF Finance
- GNFT Health Care
- Exchange
- DHF Nasdaq
- GNFT Nasdaq
- Market Cap
- DHF 188.4M
- GNFT 172.2M
- IPO Year
- DHF N/A
- GNFT 2019
- Fundamental
- Price
- DHF $2.61
- GNFT $3.66
- Analyst Decision
- DHF
- GNFT Strong Buy
- Analyst Count
- DHF 0
- GNFT 1
- Target Price
- DHF N/A
- GNFT $13.00
- AVG Volume (30 Days)
- DHF 451.1K
- GNFT 6.9K
- Earning Date
- DHF 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- DHF 7.65%
- GNFT N/A
- EPS Growth
- DHF N/A
- GNFT N/A
- EPS
- DHF N/A
- GNFT 0.47
- Revenue
- DHF N/A
- GNFT $86,225,222.00
- Revenue This Year
- DHF N/A
- GNFT $145.20
- Revenue Next Year
- DHF N/A
- GNFT N/A
- P/E Ratio
- DHF N/A
- GNFT $7.56
- Revenue Growth
- DHF N/A
- GNFT 175.45
- 52 Week Low
- DHF $2.06
- GNFT $3.35
- 52 Week High
- DHF $2.39
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- DHF 54.44
- GNFT 44.80
- Support Level
- DHF $2.53
- GNFT $3.35
- Resistance Level
- DHF $2.62
- GNFT $3.57
- Average True Range (ATR)
- DHF 0.03
- GNFT 0.11
- MACD
- DHF 0.01
- GNFT 0.02
- Stochastic Oscillator
- DHF 84.30
- GNFT 56.36
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.